GSK Announces Positive Outcomes from Late-Stage Gonorrhoea Treatment Trial

GSK has reported positive outcomes from a late-stage study on gepotidacin, an oral treatment for urogenital gonorrhoea in adults.  

The study aimed to evaluate the safety profile of gepotidacin when compared with a standard treatment, azithromycin, and intramuscular ceftriaxone.  

Based on the results, gepotidacin showed comparable effectiveness, achieving a success rate of just over 90%, similar to the success rate of the standard treatment.  

In the study, gepotidacin demonstrated safety and tolerability consistent with findings from initial investigations.  

Chris Corsico, deputy chief of development at GSK, commented, “These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide, including drug-resistant infections.”   

Corsico went on to add, “The imperative for innovative treatments has never been clearer. We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.